1.Sales and profit
See section β- Scholar Rock Holding Corp had $0.0M of revenue in fiscal 2025.
- Scholar Rock Holding Corp lost $378M in fiscal 2025.
SRRK Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017βFY2025
Scholar Rock Holding Corp had $0.0M of revenue in fiscal 2025.
Last close Β· Oct 23, 2026
$41.49
1.1%Hi! I read Scholar Rock Holding Corpβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
β$378M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Scholar Rock Holding Corp did it, and the next one. Share prices often move a lot on those days.
Next results
November 10, 2026
Tuesday Β· in 15 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 7, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 14, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 6, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 14, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Feb 27, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 12, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Scholar Rock Holding Corp had $0.0M of revenue in fiscal 2025.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
KIRA Β· Scholar Rock Holding Corp lost $378M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$301M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Scholar Rock Holding Corp has $268M more cash than debt.
Cash, debt and the ratios that show how comfortably Scholar Rock Holding Corp can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $253M | $315M | $280M | $437M | $368M |
| Debt incl. finance leases | $53.6M | $51.0M | $52.3M | $50.1M | $99.7M |
| Debt / equity | 0.3x | 0.2x | 0.2x | 0.1x | 0.4x |
| Interest coverage | β61.9x | β28.6x | β26.4x | β36.9x | β55.8x |
| Current ratio | 4.1x | 9.0x | 8.8x | 9.6x | 6.9x |
| Quick ratio | 4.1x | 9.0x | 8.8x | 9.6x | 6.9x |
| Total assets | $304M | $358M | $311M | $475M | $404M |
| Total liabilities | $132M | $97.9M | $85.8M | $106M | $159M |
| Shareholders' equity | $172M | $260M | $225M | $369M | $245M |
| Net debt (β = net cash) | β$199M | β$264M | β$228M | β$387M | β$268M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Scholar Rock Holding Corp passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 2 / 7 | 3 / 7 | 2 / 8 | 5 / 8 | 1 / 7 | 4 / 7 | 1 / 7 |
| Accruals ratio | β5.3% | β60.8% | 6.4% | β9.0% | β1.4% | β0.5% | β6.1% | β11.5% | β17.7% |
| Altman Z'' | β9.49 | 3.01 | 2.02 | 3.69 | β1.20 | 0.96 | β2.65 | β0.68 | β9.91 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $0.0M | $0.0M | $20.5M | $15.4M | $18.8M | $33.2M | β | β | $0.0M |
| Net interest income | $0.0M | $1.4M | β | β | β | β | β | β | β |
| Research and development | $19.9M | $36.3M | $54.2M | $74.1M | $108M | $124M | $122M | $185M | $208M |
| Operating income | β$25.0M | β$50.7M | β$54.5M | β$86.9M | β$130M | β$134M | β$171M | β$252M | β$385M |
| Interest expense | β | β | $0.0M | $0.4M | $2.1M | $4.7M | $6.5M | $6.8M | $6.9M |
| Pretax income | β | β | β | β | β | β | β | β$246M | β$378M |
| Net income | β$25.0M | β$49.3M | β$51.0M | β$86.5M | β$132M | β$135M | β$166M | β$246M | β$378M |
| Diluted EPS | β$15.30 | β$3.15 | β$1.85 | β$2.81 | β$3.59 | β$2.26 | β$1.99 | β$2.47 | β$3.29 |
| Diluted shares | 0.00B | 0.02B | 0.03B | 0.03B | 0.04B | 0.06B | 0.08B | 0.10B | 0.11B |
| Cash flow | |||||||||
| Cash from operations | β$21.7M | $24.6M | β$63.1M | β$60.3M | β$127M | β$133M | β$145M | β$201M | β$300M |
| Capital expenditure | $0.4M | $1.5M | $3.1M | $4.1M | $5.2M | $1.1M | $0.1M | $0.1M | $0.6M |
| Free cash flow | β$22.1M | $23.1M | β$66.2M | β$64.4M | β$132M | β$134M | β$145M | β$201M | β$301M |
| Depreciation and amortization | $0.7M | $0.8M | $1.3M | $1.5M | $2.6M | $3.0M | $2.8M | $1.9M | $1.7M |
| Stock-based compensation | $1.5M | $5.2M | $8.0M | $11.2M | $23.1M | $27.7M | $27.1M | $36.6M | $75.6M |
| Balance sheet | |||||||||
| Cash and short-term investments | $58.0M | $176M | $157M | $341M | $253M | $315M | $280M | $437M | $368M |
| Total debt | $1.0M | $0.5M | β | $26.0M | $53.6M | $51.0M | $52.3M | $50.1M | $99.7M |
| Current assets | $59.2M | $178M | $185M | $344M | $265M | $328M | $288M | $451M | $385M |
| Current liabilities | $5.0M | $31.1M | $32.8M | $42.6M | $64.3M | $36.4M | $32.7M | $46.9M | $55.4M |
| Property and equipment, net | $2.2M | $3.2M | $4.2M | $8.1M | $9.6M | $7.4M | $4.6M | $2.8M | $1.7M |
| Total assets | $61.6M | $181M | $196M | $388M | $304M | $358M | $311M | $475M | $404M |
| Total liabilities | $5.9M | $74.7M | $83.5M | $128M | $132M | $97.9M | $85.8M | $106M | $159M |
| Preferred stock | β | β | β | β | β | β | β | β | $0.0M |
| Shareholders' equity | β$53.5M | $107M | $113M | $261M | $172M | $260M | $225M | $369M | $245M |
| Margins | |||||||||
| Operating margin | β56,884.1% | β | β266.2% | β564.0% | β690.5% | β404.8% | β | β | β |
| EBITDA margin | β55,363.6% | β | β259.8% | β554.4% | β676.5% | β395.8% | β | β | β |
| Net margin | β56,806.8% | β | β248.9% | β561.5% | β700.5% | β405.2% | β | β | β |
| FCF margin | β50,222.7% | β | β323.2% | β417.8% | β701.7% | β403.0% | β | β | β |
| Net interest share of revenue | 100.0% | β | β | β | β | β | β | β | β |
| Returns | |||||||||
| Return on capital employed | β44.2% | β33.7% | β33.3% | β25.1% | β54.1% | β41.8% | β61.6% | β58.9% | β110.3% |
| Return on equity | β | β185.8% | β46.5% | β46.3% | β60.9% | β62.2% | β68.3% | β82.9% | β123.1% |
| Return on assets | β40.6% | β40.6% | β27.0% | β29.6% | β38.1% | β40.6% | β49.5% | β62.7% | β86.0% |
| Return on tangible equity | β | β46.3% | β45.2% | β33.2% | β76.6% | β51.7% | β73.6% | β66.8% | β154.0% |
| Growth | |||||||||
| Revenue growth | β | β100.0% | β | β24.8% | 22.2% | 76.4% | β | β | β |
| FCF growth | β | β | β387.0% | β | β | β | β | β | β |
| Share count change | β | 858.0% | 75.9% | 11.6% | 19.4% | 62.4% | 39.8% | 19.8% | 14.9% |
| Financial health | |||||||||
| Debt / equity | β | 0.0x | β | 0.1x | 0.3x | 0.2x | 0.2x | 0.1x | 0.4x |
| Interest coverage | β | β | β2,020.1x | β217.2x | β61.9x | β28.6x | β26.4x | β36.9x | β55.8x |
| Current ratio | 11.8x | 5.7x | 5.6x | 8.1x | 4.1x | 9.0x | 8.8x | 9.6x | 6.9x |
| Quick ratio | 11.8x | 5.7x | 5.6x | 8.1x | 4.1x | 9.0x | 8.8x | 9.6x | 6.9x |
| Capital allocation | |||||||||
| Capex / revenue | 820.5% | β | 15.2% | 26.5% | 27.9% | 3.2% | β | β | β |
| Stock comp / revenue | 3,368.2% | β | 38.9% | 72.6% | 123.0% | 83.5% | β | β | β |
| Quality scores | |||||||||
| Piotroski F-score | β | 4.0 | 2.0 | 3.0 | 2.0 | 5.0 | 1.0 | 4.0 | 1.0 |
| Altman Z'' | β9.5 | 3.0 | 2.0 | 3.7 | β1.2 | 1.0 | β2.6 | β0.7 | β9.9 |
| Accruals ratio | β5.3% | β60.8% | 6.4% | β9.0% | β1.4% | β0.5% | β6.1% | β11.5% | β17.7% |
Source: SEC EDGAR XBRL filings (CIK 0001727196). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.